- Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University
- This was part of a collaboration established with the university’s technology transfer company, Yissum
- These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications
- Clearmind is a psychedelic pharmaceutical biotech company
- Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET
Clearmind (CMND) has completed two R&D projects with leading scientists from multiple disciplines at the Hebrew University.
This was part of a collaboration established with the university’s technology transfer company, Yissum. Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry.
The first project was led by Professor Dmitry Tsvelikhovsky, Professor Masha Niv and Professor Avi Priel. It was designed to investigate and discover innovative synthetic molecules based on known psychedelic chemical motifs. The project included the rational design of novel candidates and in-silico 3D docking studies on the 5HT2A serotonin receptor. It screened the candidates in an in-vitro platform to assess the receptor activation.
The second project was led by Professor Ahmad Masarwa, Professor Avi Priel, and Professor Rami Yaka. It was aimed to synthesize and evaluate the potential therapeutic effect of various chemical psychedelic analogues. The work included alterations of different regions of known molecules to potentially improve their binding capabilities to the 5HT2A receptor. The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.
These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.
Clearmind is a psychedelic pharmaceutical biotech company. Its objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Clearmind Medicine Inc. (CMND) is up 2.74 per cent, trading at C$6.00 per share at 10:34 am ET.
